^
Association details:
| Biomarker: | KRAS mutation + BCL2A1 overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment
Published date:
11/01/2018
Excerpt:
Samples with KRAS mutations demonstrated high BCL2A1 expression, which potentially mediate venetoclax resistance.
DOI:
https://doi.org/10.1182/blood-2018-175
